Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study
British Journal of Cancer, 11/03/09

Board RE et al. – These data demonstrate the feasibility of BRAF mutation detection in cfDNA of patients with advanced melanoma. Future studies should aim to incorporate BRAF mutation testing in cfDNA to further validate this biomarker for patient selection.

Methods

BRAF mutations detected using Amplification Refractory Mutation System allele-specific PCR
BRAF mutation status assessed in serum-derived cfDNA from 126 patients enrolled into study and from 94 matched tumour samples

Results

Of 94 tumour samples, 45 (47.9%) found to be BRAF mutation positive (BRAF+)
Serum-derived cfDNA was BRAF+ in 33 of 126 (26.2%) samples, including in 5 samples for which tumour data unavailable
Of BRAF+ tumours, 25 of 45 (55.6%) were BRAF+ in cfDNA
In 3 cases in which tumour was negative, cfDNA was BRAF+
PFS of patients with BRAF+ tumour and cfDNA not significantly different compared with tumour BRAF+ but cfDNA BRAF-negative patients, indicating cfDNA BRAF detection not associated with poorer prognosis on PFS in stage III/IV advanced melanoma

<< Previous
Serum calcium levels are elevated among women with untreated...

Next >>
Dose finding and early efficacy study of gemcitabine plus...